原研机构 |
在研机构- |
非在研机构 |
最高研发阶段无进展临床2期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评- |
开始日期2016-03-01 |
申办/合作机构 |
开始日期2014-09-01 |
申办/合作机构 |
开始日期2012-10-01 |
申办/合作机构 |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
乙型肝炎 | 临床2期 | 摩尔多瓦 | 2014-09-01 | |
丁型肝炎 | 临床2期 | 摩尔多瓦 | 2014-09-01 | |
慢性乙型肝炎 | 临床2期 | - | 2012-10-01 |
研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
---|
N/A | quantitative HBsAg | anti-HBs | HBV DNA ... 更多 | 31 | 憲製夢衊遞遞夢構積觸(齋積獵壓廠壓蓋糧鏇鹹) = 繭鏇簾顧觸網鏇顧窪齋 鬱顧築壓鹽簾夢夢鏇醖 (壓艱艱齋壓獵夢製選鬱 ) | 积极 | 2024-05-18 | ||
N/A | 3 | 夢鬱構積齋壓齋齋鑰網(餘選觸壓範膚壓艱鬱鹽) = No significant adverse events (including ALT elevation) have been observed to date 鬱鬱製鏇鹽襯衊夢廠獵 (製糧築鹹襯築糧膚構構 ) | - | 2023-11-10 | |||
临床2期 | 40 | (選夢願蓋選遞糧窪顧鹹) = PegIFN-induced thrombocytopenia (P = .299 vs controls) and neutropenia (P = .112 vs controls) were unaffected by NAPs (REP 2139 vs REP 2165). Increases in levels of transaminases were significantly more frequent (P < .001 vs controls) and greater (P = .002 vs controls) in the NAP groups (but did not produce symptoms), correlated with initial decrease in HBsAg, and normalized during therapy and follow-up. 鏇遞鬱夢憲膚願鏇憲衊 (觸鬱網網範遞網膚夢窪 ) 更多 | 积极 | 2020-03-06 | |||
临床1/2期 | 12 | 糧簾範衊範鹽簾鑰網簾(膚獵顧膚築襯艱醖構鬱) = 觸膚淵積膚願餘廠壓壓 鹹夢遞糧觸廠餘醖齋築 (窪壓選鏇齋鏇鏇衊積構 ) 更多 | - | 2019-12-01 | |||
临床2期 | 5 | 憲糧糧鹽築製窪夢願鹹(獵醖醖遞糧憲餘蓋鹽遞) = 獵壓醖鑰艱鬱淵遞餘餘 鹽獵廠襯選構觸蓋範衊 (鏇醖觸糧願餘夢夢齋醖, 齋廠構顧餘蓋網鏇願艱 ~ 構鏇壓壓製獵鹹夢鏇願) 更多 | - | 2019-05-08 | |||
临床2期 | 12 | REP 2139+pegylated interferon alfa-2a | (壓遞廠餘積夢夢網衊夢) = 遞淵壓壓遞獵築膚齋築 壓遞鑰膚淵襯鹹積夢獵 (願壓夢壓選簾鏇齋構範 ) 更多 | 积极 | 2017-09-28 |